The start-ups and research projects work within the three life science industries: therapeutics, health tech and bioindustrials. The start-ups and projects are developing a diverse range of products and solutions ranging from using an innovative approach to using CRISPR Cas-12 variants to be safely used in gene-editing, a new amyotrophic lateral sclerosis (ALS) treatment, a gut approach to treating osteoporosis, a range of biological products against aquatic pests and diseases, and the development of new therapies for diabetic retinopathy to prevent vision loss and blindness in patients.
Jens Nielsen, professor, and CEO at BioInnovation Institute says: “BII helps early-stage start-ups become investment ready by bridging the gap between academia and business. I am happy to welcome the new high-potential companies and research projects in BII’s community to provide them with the best opportunities to develop their innovation. I am looking forward to following the companies’ accelerated path towards the market with the knowledge, network, funding, and infrastructure required for start-up success.”
Read full press release from BII here and learn which companies and projects are now part of the BII- and Medicon Valley Alliance family.
